Search Results

You are looking at 1 - 4 of 4 items for :

  • "dual x-ray absorptiometry" x
Clear All
Full access

Dennis R. Taaffe, Robert U. Newton, Nigel Spry, David J. Joseph and Daniel A. Galvão

) and FM, trunk FM (TrFM), and appendicular skeletal muscle (ASM) were derived from a whole-body dual x-ray absorptiometry scan (Hologic Discovery A; Hologic, Inc.). ASM was calculated as the sum of upper limb and lower limb bone-free LM. 16 Muscle

Full access

Richard L. Theriault, J. Sybil Biermann, Elizabeth Brown, Adam Brufsky, Laurence Demers, Ravinder K. Grewal, Theresa Guise, Rebecca Jackson, Kevin McEnery, Donald Podoloff, Peter Ravdin, Charles L. Shapiro, Matthew Smith and Catherine H. Van Poznak

age or sex. Bone mineral density (BMD) measurements with DXA (dual x-ray absorptiometry) can vary with the instrument used and the anatomic site assessed; therefore, serial monitoring of BMD should be performed on the same piece of equipment using the

Full access

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas and Catherine H. Van Poznak

Bone health and maintenance of bone integrity are important components of comprehensive cancer care in both early and late stages of disease. Risk factors for osteoporosis are increased in patients with cancer, including women with chemotherapy-induced ovarian failure, those treated with aromatase inhibitors for breast cancer, men receiving androgen-deprivation therapy for prostate cancer, and patients undergoing glucocorticoid therapy. The skeleton is a common site of metastatic cancer recurrence, and skeletal-related events are the cause of significant morbidity. The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force on Bone Health in Cancer Care to discuss the progress made in identifying effective screening and therapeutic options for management of treatment-related bone loss; understanding the factors that result in bone metastases; managing skeletal metastases; and evolving strategies to reduce bone recurrences. This report summarizes presentations made at the meeting.

Full access

John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud and Joan M. Neuner

women starting AI therapy with bone density testing with dual x-ray absorptiometry (DXA) or other technologies is recommended by current ASCO and NCCN guidelines. 5 , 6 Subsequent treatment decisions should be based on results of bone density tests